Printer Friendly

SYNERGEN EXPANDS INTO EUROPE

 SYNERGEN EXPANDS INTO EUROPE
 BOULDER, Colo., Nov. 25 /PRNewswire/ -- Synergen Inc.


(NASDAQ: SYGN) announced today it has recruited its first employee in Europe, Nigel G. Goodman. He will assume the position of director of European marketing and business affairs for Synergen's European operation, to be located in Amsterdam, The Netherlands.
 Goodman joins Synergen after a 17-year career at Hoffmann-La Roche, where he served, among numerous positions of increasing responsibility, as international product manager for Roferon, Roche's first biopharmaceutical product. He then served as project team leader of the Amgen-Roche G-CSF joint venture. Goodman later became the Amgen-Roche marketing director, overseeing the joint venture's Neupogen interests in Europe, Latin America, the Middle East and Pacific Rim. Most recently, Goodman was an account director at Gardiner Caldwell Communications, which provides medical education services to the pharmaceutical industry.
 Goodman is a graduate of the University of Liverpool with a B.S. in Physiology. He also received a degree in management studies from the Manchester University Business School.
 Synergen is a biopharmaceutical company engaged in the discovery, development and manufacture of protein-based pharmaceuticals.
 -0- 11/25/91
 /CONTACT: Debra Catz Bannister of Synergen, 303-938-6242/
 (SYGN) CO: Synergen Inc. ST: Colorado IN: MTC SU:


BB -- DV003 -- 6922 11/25/91 14:26 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 25, 1991
Words:208
Previous Article:PENSION BENEFIT GUARANTY CORPORATION'S TOP 50 LIST SHOWS INCREASED UNDERFUNDING
Next Article:GENERAL MOTORS ANNOUNCES SIGNING OF FIRST MULTI-CITY DISTRIBUTOR OF NORTH AMERICAN VEHICLES IN THE SOVIET UNION
Topics:


Related Articles
SYNERGEN REVISES PARTNERSHIP OFFER
SYNERGEN ADDS PATENT ATTORNEY AT BOULDER HEADQUARTERS
SYNERGEN INITIATES PHASE III TRIAL FOR ANTRIL
SYNERGEN APPOINTS DIRECTOR OF QUALITY
SYNERGEN ANNOUNCES NEW OFFICER AND MANAGEMENT APPOINTMENTS
SYNERGEN COMPLETES PHASE III CLINICAL TRIAL ENROLLMENT FOR ANTRIL IN SEPSIS; 900 PATIENTS RECRUITED IN THE U.S., CANADA AND EUROPE
SYNERGEN BEGINS OPERATIONS IN JAPAN
SYNERGEN REPORTS 1992 FINANCIAL RESULTS
NEW SYNERGEN SEPSIS TRIAL ENROLLS FIRST PATIENT; FOLLOW-UP TRIAL IN SEVERE SEPSIS PATIENTS BEGINS ON SCHEDULE
SYNERGEN ELECTS NEW DIRECTOR TO BOARD

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters